Balyasny Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$45.3M	Buy	2,315,957 +1,812,089	+360%	+$53.8M	0.09%	384
2025 Q4	$15.7M	Buy	503,868 +301,047	+148%	+$8.26M	0.03%	842
2025 Q3	$4.38M	Buy	+202,821	New	+$3.66M	0.01%	1423
2025 Q1	–	Sell	-130,721	Closed	-$2.51M	–	3380
2024 Q4	$2.51M	Sell	130,721 -208,368	-61%	-$4.53M	0.01%	1592
2024 Q3	$7.71M	Buy	+339,089	New	+$5.54M	0.02%	1070
2024 Q1	–	Sell	-41,214	Closed	-$898K	–	3194
2023 Q4	$898K	Buy	41,214 +27,245	+195%	+$430K	﹤0.01%	1730
2023 Q3	$214K	Buy	+13,969	New	+$266K	﹤0.01%	2012
2023 Q1	–	Sell	-304,552	Closed	-$8.9M	–	3231
2022 Q4	$8.9M	Buy	304,552 +135,023	+80%	+$3.11M	0.03%	787
2022 Q3	$3.48M	Buy	+169,529	New	+$3.05M	0.01%	1204
2022 Q2	–	Sell	-16,303	Closed	-$301K	–	3295
2022 Q1	$301K	Buy	+16,303	New	+$313K	﹤0.01%	1923
2021 Q3	–	Sell	-119,478	Closed	-$2.19M	–	2551
2021 Q2	$2.19M	Sell	119,478 -98	-0.1%	-$1.68K	0.01%	981
2021 Q1	$2M	Buy	+119,576	New	+$2.24M	0.01%	1023